Biofrontera AG has announced a binding agreement with Biofrontera Inc. to ensure the long-term continuity of its business operations in the United States. As part of the transaction, Biofrontera AG will receive a 10% stake in Biofrontera Inc., along with ongoing royalty payments of 12% to 15% on U.S. sales of Ameluz®. The agreement also includes a one-year lock-up commitment by Biofrontera Inc., prohibiting further dilutive capital increases without prior consent from Biofrontera AG. Effective June 1, 2025, all assets and liabilities related to the commercialization of Ameluz® in the U.S. will be transferred to Biofrontera Inc. This strategic restructuring aims to reduce risks and costs for Biofrontera AG while ensuring a stable financial basis for Biofrontera Inc.'s U.S. activities through an $11 million financing round supported by investors.